How dependent is India on Anti-Cancer APIs (Cytotoxic) imports?

India imports $0.26 bn, mostly from Italy. Its Critical Manufacturing Dependency Index is 70.35/100 (High), with a localisation potential of 58.

Anti-Cancer APIs (Cytotoxic)

High dependencyBuild-nowPharmaceuticals & APIsReasoned estimateHS 2941.90

$0.26 bnAnnual import

35%Indian capability

4,882Supplier concentration (HHI)

₹1,833 crTo localise

Why India imports it. Reasoned estimate: India has limited domestic capacity for anti-cancer apis (cytotoxic); sector trade patterns indicate continued import reliance.

Why it matters. Strategic dependency within pharma value chain; affects downstream manufacturing competitiveness.

Can India localise it? Partial

Where it comes from. Italy (59%), China (26%), USA (15%).

Scorecard

The ten indices

CMDI 70.35Dependency

LPI 58Localisation potential

IAI 66.25Investment attractiveness

SRI 66.01Supply risk

SCI 51.5Supply-chain complexity

TRI 43.75Technology readiness

IMI 66.5Industrial multiplier

NSRI 57.25National-security relevance

EPI 65.25Export potential

ICGI 57.25Capability gap

Intelligence

Related signals

Sources

Primary references

pharmaceuticals.gov.in ↗

Confidence: Reasoned estimate. Reasoned estimate derived from sector trade patterns and HS code classification; specific company/number values are modelled. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).